GOTHENBURG, Sweden, April 23, 2026 /PRNewswire/ --
First quarter
- Sales of SEK 807 (842) million, an increase of 5% in local currencies and 4% decrease in SEK.
- Sales per region, in local currencies, were -1% in EMEA, +11% in Americas and +7% in APAC.
- Sales per product group, in local currencies were +9% in Consumables, +11% in Technologies and -1% in Genetics.
- Gross margin increase to 59.9% (57.4).
- Earnings before depreciation and amortisation (EBITDA) amounted to SEK 251 (257) million, resulting in an EBITDA margin of 31.1% (30.6).
- Net income amounted to SEK 101 (100) million, resulting in earnings per share of SEK 0.74 (0.74).
- Operating cash flow amounted to SEK 172 (69) million.
Gothenburg, April 23, 2026
VITROLIFE AB (publ)
Bronwyn Brophy O´Connor, CEO
This disclosure contains information that Vitrolife AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 23-04-2026 08:00 CET.
Contact:
Pär Ihrskog, CFO
e-mail: investors@vitrolife.com
phone: +46 (0) 31 721 80 00
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Interim report Q1, 2026 |
View original content:https://www.prnewswire.com/news-releases/vitrolife-ab-publ---interim-report-q1-2026-strong-growth-in-consumables-and-technologies-302751418.html
SOURCE Vitrolife AB (publ)
